Articles On Arc Exploration (ASX:ARX)

ASX small caps come with heightened risk, but increased upside compared to blue-chip shares. However some investors may choose to allocate some portion of their portfolio to these kinds of equities.  If you are looking to monitor sma...

Surgeons discuss their positive experience of using Aroa’s Myriad products for burns and complex wounds US trauma and emergency surgeon Dr Alison Smith said Myriad was a versatile treatment option for the wide array of wounds encountered i...

Highlights Staples drag the index lower amid cost pressures Energy sector gains strength on rising oil momentum Lithium players stay resilient with upbeat sentiment The Australian market extended its losing streak as w...

ASX closes lower despite eight sectors finishing in the green Staples smashed as Woolies and Coles sold off sharply Lithium keeps climbing on stronger Chinese futures   It’s eight days straight of S&P/ASX 200 blood. The closing clang...

Aroa reports preliminary revenue of NZ$104 million for FY26, above guidance and up 21% Normalised EBITDA of NZ$11-12m, well ahead of NZ$5-8m guidance  Positive net cash flow of NZ$5m for year with cash balance rising to NZ$27m    Special...

Aroa shares leap 17% after management flags a full-year earnings beat Impedimed hopes GLP-1 drugs will fatten its profits Little Green hits a European purple patch   Kiwi-based wound care house Aroa Biosurgery (ASX:ARX) has defied the glo...

The All Ordinaries Index (ASX: XAO) is down 0.3% in late morning trade on Thursday, but don't blame this rocketing ASX All Ords healthcare share. The high-flying stock in question is Aroa Biosurgery Ltd (ASX: ARX). Shares in the soft-tissu...

What does US reimbursement actually mean for the skin substitute market? Why has a major pricing reset grabbed attention in 2026? And how is it changing the way products are adopted? Aroa Biosurgery (ASX:ARX) founder and CEO Brian Wa...

ASX lifts from lows of -1.5% to slide -0.65 Energy, utilities, materials, consumer staples make gains Banks and info tech retreat sharply   Aluminium and gold gains limit losses The S&P/ASX 200 had fallen 0.65% by trade’s end, shoved...

Aroa’s Symphony randomised controlled trial in diabetic foot ulcers completed Preliminary findings indicate the trial met its primary endpoint, outperforming standard of care Publication of the study expected to support Symphony’s clinical...

A slew of biotechs are raising funds on the back of positive announcements Genetic Signatures wields the scythe in cost-cutting blitz Aroa completes a key trial while Cynata is almost done, too Junior ASX biotechs are successfully raising...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Aroa Biosurgery (ASX:ARX) VP of Medical Affairs Dr Adam Young about the rapid expansion of...

Stockhead’s Tylah Tully previews the 2026 ahead for Aroa Biosurgery (ASX:ARX) and recaps the goals the company achieved throughout 2025. Tune in to hear all the details.   This video was developed in collaboration with Aroa Biosurgery, a St...

ASX stages swift recovery, climbing 0.89% or 78 points 10 of 11 sectors on the up; just utilities left in the cold Info tech and materials lead gains   Market powers through RBA rate hike The market recovered its footing after four sessio...

Aroa reconfirms FY26 guidance of NZ$92-100 million total revenue and normalised EBITDA of NZ$5-8 million  Company expects FY26 results to fall at upper end of guidance range after strong quarter Favourable regulatory reimbursement changes...

ASX tips up just 0.13% or 11.4 points 7 sectors lower, 106/200 stocks falling Info tech and gold stocks power higher Tech sector stages recovery It was a decidedly uneventful day of trade on the ASX 200 today. The bourse ticked up just 1...

New data from Aroa’s ongoing prospective MASTRR study published in the Journal of Trauma and Injury  Data demonstrates successful outcomes and cost savings using Myriad bioscaffolds in complex trauma and acute care surgery  Across four le...

Aroa’s multi-channel sales strategy driving global growth of its soft-tissue repair products Aroa has a partnership with TELA Bio in US and also sells directly in the country with other distributors internationally Biotech moving towards l...

ASX health sector rises 4.3% for the week in rotation back to sector, while broader market rises 0.8%  Ramsay’s shares lift as investors react positively to news of a transformation strategy for its Australian private hospitals business Mo...

The team at Bell Potter have just released fresh analysis on ASX small-cap stock Aroa Biosurgery Limited (ASX: ARX).  It is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and d...

Tylah Tully speaks with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward about the company’s first HY FY26 results, which delivered NZ$44.9 million in revenue driven by strong growth in its Myriad product. The company reported its fourt...

ASX struggles into the positive to add 0.14% Gold stocks, info tech lead gains Banks drag as BEN’s compliance issues bite   Gold gains outweigh banking ballast The banking sector took the wind out of the ASX’s sails today, suffering a spo...

Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.

With 12 months of consistent positive cash flow, Aroa Biosurgery no longer needs to lodge quarterly reports Monash IVF’s bidder will have to pay more  Pacific Edge positions itself for reimbursement resumption   Aroa Biosurgery’s (ASX:ARX...

ASX closes 3.60 points lower after falling in afternoon session Mayne Pharma falls ~32% after Australian government opposes proposed takeover ASX gold stocks lead materials sector higher after bullion prices rebound 2% overnight    The AS...

Seasoned global healthcare executive Paul Shearer to join Aroa Biosurgery as a non-executive director Shearer spent more than 30 years at Fisher & Paykel Healthcare, playing a key role in its US expansion The appointment comes as long-...

The ASX health sector moved up 1.30% for the week, while the broader market inched up 0.12% Aroa recorded fourth consecutive quarter of positive net cash flow with Myriad breaking records Orthocell raised $30 million in oversubscribed plac...

ASX closes 0.86% higher to reach a new 100-day high after hitting an intraday record  Australia’s unemployment rate climbs to four-year high of 4.5% in September, up from revised 4.3% in August Rate sensitive sectors including real estate,...

The NSW Supreme Court has, in effect, ruled against Cosette’s attempt to abandon its $670m takeover of Mayne Pharma Cogstate posts record quarterly sales on the back of surging demand for depression and schizophrenia testing Aroa posts st...

Aroa records fourth consecutive quarter of positive net cash flow  Highest quarter on record for high-margin Myriad products with NZ$10.2 million in sales FY26 guidance of NZ$92-100 million reaffirmed with Normalised EBITDA for FY26 of NZ$...

Regenerative medicine is a fast-growing healthcare field that harnesses the body’s natural healing ability At Monash University, the Australian Regenerative Medicine Institute is internationally recognised for pioneering research Several A...

Healthcare analysts say Aroa Biosurgery positioned to benefit from upcoming changes to US wound care market Centers for Medicare & Medicaid Services set to overhaul how skin substitutes are reimbursed, removing price driven incentives...

CSL shares have taken another 8% bath, even though brokers maintain valuations well above the current level Aroa Biosurgery says growing non-US sales should offset the impact of Trumpian tariffs “Opthea 2.0” is likely to stick with its kni...

ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback  ‘Mostly pretty good’ June quarterly reporting season comes to end  Clarity Pharmaceuticals completes $203 million capital raise to institutional i...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

Energy stocks climb as oil ticks up 2pc ASX rallies late to climb 0.08pc Gold stocks slide despite recovering gold price   ASX lifts as clouds part for energy sector The ASX was in a decidedly bad mood today, hanging out in negative terri...

Morgans’ Scott Power says path to profitability is key to a successful emerging ASX health care company While innovation is important, Power says the market loses interest in companies which don’t turn a profit Wound care company Aroa Bios...

New blood test reveals hidden muscle damage in racehorses Proteomics’ OxiDx helps trainers spot injuries early and avoid breakdowns ASX-listed stocks with exposure to the animal sector.   In the high-octane world of thoroughbred racing, m...

Sales of Aroa’s high-margin Myriad family expected to further propel growth in FY26 and beyond Myriad sales were NZ$30.8 million of the total NZ$84.7m for FY25, representing 38% growth on FY24  Direct sales team momentum and growing body o...

Highlights ASX 200 closes at a new all-time high driven by strength in financials and gold sectors Major banks and insurers post solid gains, lifting the Financials Index Gold producers lead materials sector gains amid commo...

If you have a high tolerance for risk and are on the hunt for big returns, then look no further. That's because analysts at Bell Potter have named the two small cap ASX shares listed below as buys with potential to deliver outsized returns....

Highlights ASX health sector shows strength relative to broader market performance HealthCo REIT (ASX:HCW) reaches rental deferral arrangement with Healthscope receivers Aroa Biosurgery (ASX:ARX) posts inaugural full-year pr...

ASX health stocks up 1.2% over past five days while the broader market is up 0.8%  HealthCo REIT agrees to short-term partial rent deferral with troubled Healthscope and its receivers New-Zealand-based soft-tissue repair company Aroa Biosu...

Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company’s FY25 results, posting its first profit since listing on the ASX in 2020.  The company had a strong year, reporting total revenue of NZ$84.7 million...

Aroa surges to profitability in FY25 with a NZ$4.2 million normalised EBITDA profit  Reports total revenue for full year of NZ$84.7 million, up 23% and exceeding guidance Provides total revenue guidance for FY26 of NZ$92-100 million, up 10...

Tylah Tully speaks with Aroa Biosurgery (ASX:ARX) senior medical science liaison Dr Brandon Bosque about how Aroa’s groundbreaking ECM technology, backed by 100 peer-reviewed studies, is aiming to revolutionise wound care. Bosque shares the...

ASX heath sector falls 1.3%, trailing ASX 200 up 1.1% as macro picture remains uncertain but ‘little bit better’ Soft-tissue repair company Aroa Biosurgery reconfirms FY25 reported revenue guidance of NZ$81-84 million Medical imaging softe...

Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating...

AROA lifts after recording its second consecutive quarter of positive cash flows from operations Full-year FY25 guidance remains unchanged at NZ$81-$84 million in total revenue Sales of AROA’s high-margin Myriad family in March top the hig...

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...